{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-Esophageal+Adenocarcinoma&page=9", "query": { "condition": "Gastro-Esophageal Adenocarcinoma", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 324, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-Esophageal+Adenocarcinoma&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-Esophageal+Adenocarcinoma&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T23:45:35.461Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer" ], "interventions": [ { "name": "ZW25 (Zanidatamab)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2019-08-29", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 11, "location_summary": "Los Angeles, California • Newport Beach, California • Tampa, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03929666" }, { "nct_id": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer" ], "interventions": [ { "name": "MDNA11", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2021-08-27", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086692" }, { "nct_id": "NCT00048529", "title": "Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Esophageal Neoplasms" ], "interventions": [ { "name": "T900607-sodium intravenous", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tularik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2002-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 5, "location_summary": "Los Gatos, California • San Diego, California • Tampa, Florida + 2 more", "locations": [ { "city": "Los Gatos", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048529" }, { "nct_id": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "Part A", "type": "BIOLOGICAL" }, { "name": "Part B", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TopAlliance Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2018-02-21", "completion_date": "2022-07-07", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 14, "location_summary": "Santa Monica, California • Aurora, Colorado • Miami, Florida + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03474640" }, { "nct_id": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Cervical Cancer", "Head and Neck Squamous Cell Cancer", "Triple Negative Breast Cancer (TNBC)", "Urothelial Carcinoma Bladder", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Gastric Cancer", "Cancer", "Solid Tumors (Phase 1)" ], "interventions": [ { "name": "RNDO-564", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rondo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2025-11-17", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 11, "location_summary": "San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07218003" }, { "nct_id": "NCT05329766", "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Tract Malignancies" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2022-06-10", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05329766" }, { "nct_id": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer", "Non-small Cell Lung Cancer", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GB1275", "type": "DRUG" }, { "name": "nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-08-13", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060342" }, { "nct_id": "NCT00537121", "title": "Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer", "Liver Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2006-11", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00537121" }, { "nct_id": "NCT01585987", "title": "An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Best Supportive care (BSC)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2012-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-17", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 4, "location_summary": "Miami Beach, Florida • New York, New York • Houston, Texas", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585987" }, { "nct_id": "NCT00253383", "title": "Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "counseling intervention", "type": "OTHER" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2003-01", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-12-19", "last_synced_at": "2026-10-13T23:45:35.461Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • White River Junction, Vermont", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253383" } ] }